Sugi Predict

Sugi Predict / Compounds / SCHEMBL1662722

SCHEMBL1662722

SCHEMBL1662722

COC(=O)C1CC(F)(F)C1

nearest known ligand 0.42

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ CHRNB2 P17787 2/20 0.42
▸ CHRNA4 P43681 2/20 0.42
▸ CHRNB4 P30926 1/20 0.42
▸ CHRNA3 P32297 1/20 0.42
▸ CHRNA7 P36544 1/20 0.42
▸ BRD4 O60885 1/20 0.38
▸ TP53 P04637 1/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ POLB P06746 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ CYP1A2 P05177 1/20 0.32
▸ HIF1A Q16665 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1651106 0.91 CHRNB2 (0.44) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7
SCHEMBL1651109 0.84 CHRNB2 (0.39) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7
SCHEMBL24159918 0.84 CHRNB2 (0.39) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7
SCHEMBL15776462 0.84 CHRNB2 (0.41) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7
SCHEMBL16048822 0.83 TP53 (0.38) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7
SCHEMBL26988800 0.83 CHRNB2 (0.37) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7
SCHEMBL13104069 0.83 TP53 (0.38) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7
SCHEMBL15684140 0.81 CHRM2 (0.36) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7
SCHEMBL24174889 0.81 CHRM2 (0.36) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7
SCHEMBL17756086 0.81 CHRM2 (0.36) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250129094-A1 NEW QUINOLINE DERIVATIVES ELANCO ANIMAL HEALTH GMBH (DE) 2025-04-24 — — US claimed
EP-4399209-A1 NEW QUINOLINE DERIVATIVES Elanco Animal Health GmbH (DE) 2024-07-17 — — EP claimed
WO-2023036821-A1 NEW QUINOLINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2023-03-16 — — WO claimed
EP-4148052-A1 NEW QUINOLINE DERIVATIVES Bayer Animal Health GmbH (DE) 2023-03-15 — — EP claimed
EP-4514794-B1 FGFR2 INHIBITOR COMPOUNDS LILLY CO ELI (US) 2026-03-25 — — EP disclosed
EP-4634159-A1 SULFOXIMINES AS INHIBITORS OF NAV1.8 Grünenthal GmbH (DE) 2025-10-22 — — EP disclosed
US-20250263409-A1 FGFR2 INHIBITOR COMPOUNDS ELI LILLY AND COMPANY 2025-08-21 — — US disclosed
US-20250230152-A1 PYRAZOLYL COMPOUNDS AS KV7 CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD (US) 2025-07-17 — — US disclosed
US-20250171429-A1 PYRAZOLYL COMPOUNDS AS KV7 CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD (US) 2025-05-29 — — US disclosed
US-20250129094-A1 NEW QUINOLINE DERIVATIVES ELANCO ANIMAL HEALTH GMBH (DE) 2025-04-24 — — US disclosed
EP-4514794-A1 FGFR2 INHIBITOR COMPOUNDS Eli Lilly and Company (US) 2025-03-05 — — EP disclosed
CN-119421882-A FGFR2 inhibitor compounds 伊莱利利公司 2025-02-11 — — CN disclosed
EP-3019196-A1 COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS Bristol-Myers Squibb Company (US) 2016-05-18 — — EP disclosed
US-20150297568-A1 Hepatitis C Virus Inhibitors BRISTOL MYERS SQUIBB CO (US) 2015-10-22 — — US disclosed
US-20150023913-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2015-01-22 — — US disclosed
WO-2015005901-A1 COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2015-01-15 — — WO disclosed
US-20120220624-A1 PYRAZOLO [3,4-B] PYRIDIN-4-ONE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2012-08-30 — — US disclosed
US-20120220624-A1 PYRAZOLO [3,4-B] PYRIDIN-4-ONE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2012-08-30 — — US disclosed
EP-2490693-A1 PYRAZOLO [3,4-b]PYRIDIN-4-ONE KINASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2012-08-29 — — EP disclosed
WO-2011049722-A1 PYRAZOLO [3,4-b] PYRIDIN-4-ONE KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2011-04-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250129094-A1 NEW QUINOLINE DERIVATIVES RECQL, QTRT2, NQO2 CHRNB2 1191/4885CHRNA4 590/4885CHRNB4 1420/4885
US-20250263409-A1 FGFR2 INHIBITOR COMPOUNDS FGFR2, FGFR1, FGFR3 CHRNB2 4500/4885CHRNA4 4654/4885CHRNB4 4667/4885
US-20120220624-A1 PYRAZOLO [3,4-B] PYRIDIN-4-ONE KINASE INHIBITORS CDK1, CDK5, TTBK1 CHRNB2 1484/4885CHRNA4 1781/4885CHRNB4 1342/4885
US-20150023913-A1 Hepatitis C Virus Inhibitors HAVCR2, MAVS, EIF2AK2 CHRNB2 4868/4885CHRNA4 4867/4885CHRNB4 4865/4885
US-20150297568-A1 Hepatitis C Virus Inhibitors HAVCR2, MAVS, EIF2AK2 CHRNB2 4868/4885CHRNA4 4867/4885CHRNB4 4865/4885
US-20250230152-A1 PYRAZOLYL COMPOUNDS AS KV7 CHANNEL ACTIVATORS KCNA7, KCNK17, KCNT1 CHRNB2 458/4885CHRNA4 306/4885CHRNB4 466/4885
US-20250171429-A1 PYRAZOLYL COMPOUNDS AS KV7 CHANNEL ACTIVATORS KCNA7, KCNK17, KCNT1 CHRNB2 458/4885CHRNA4 306/4885CHRNB4 466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.